Harrow Health (HROW) Stock Forecast & Price Target

Q: What is HROW’s average 12-month price target, according to analysts?

Based on analyst ratings, Harrow Health Inc’s 12-month average price target is 60.00.

Q: What is HROW’s upside potential, based on the analysts’ average price target?

Harrow Health Inc has 61.12% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is HROW a Buy, Sell or Hold?

Harrow Health Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

Q: What is Harrow Health Inc’s price target?

The average price target for Harrow Health Inc is 60.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $76.00 ,the lowest forecast is $42.00. The average price target represents 61.12% Increase from the current price of $37.24.

Q: What do analysts say about Harrow Health Inc?

Harrow Health Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

Q: How can I buy shares of HROW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

391 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HROW Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Harrow

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HROW Stock 12 Month Forecast

Average Price Target

$60.00

▲(61.12%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Harrow Health in the last 3 months. The average price target is $60.00 with a high forecast of $76.00 and a low forecast of $42.00. The average price target represents a 61.12% change from the last price of $37.24.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","77":"$77","34.25":"$34.3","48.5":"$48.5","62.75":"$62.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,34.25,48.5,62.75,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,34.24923076923077,37.72846153846154,41.20769230769231,44.68692307692308,48.16615384615385,51.645384615384614,55.12461538461538,58.603846153846156,62.08307692307693,65.5623076923077,69.04153846153847,72.52076923076923,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,33.01846153846154,35.26692307692308,37.51538461538461,39.76384615384615,42.01230769230769,44.26076923076923,46.50923076923077,48.75769230769231,51.00615384615384,53.25461538461538,55.50307692307692,57.75153846153846,{"y":60,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.77,31.633846153846154,32.497692307692304,33.36153846153846,34.22538461538461,35.08923076923077,35.95307692307692,36.816923076923075,37.68076923076923,38.54461538461538,39.40846153846154,40.27230769230769,41.136153846153846,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$76.00

Average Price Target$60.00

Lowest Price Target$42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$37

Hold

-0.64%

Downside

Reiterated

07/12/25

The overall score is driven primarily by strong earnings call insights and positive technical indicators. Financial performance is a concern due to high leverage and negative profitability, while valuation metrics are weak due to ongoing losses. Optimism from strategic initiatives and revenue growth provides a counterbalance to financial risks.

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$76

Buy

104.08%

Upside

Reiterated

07/18/25

Cantor Fitzgerald Sticks to Its Buy Rating for Harrow Health (HROW)

Yi ChenH.C. Wainwright

H.C. Wainwright

$57→$60

Buy

61.12%

Upside

Reiterated

07/18/25

Harrow Health (HROW) Receives a Buy from H.C. Wainwright

Chase KnickerbockerCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

07/17/25

Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

07/17/25

Harrow Health's Strategic Acquisition and Market Positioning Justify Buy Rating

Thomas FlatenLake Street

Lake Street

$42

Buy

12.78%

Upside

Reiterated

07/17/25

Harrow Health (HROW) Gets a Buy from Lake Street

Jeffrey CohenLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

―

Buy

―

Reiterated

07/17/25

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW)

Thomas ShraderBTIG

BTIG

$62

Buy

66.49%

Upside

Reiterated

07/01/25

First we initiated on Harrow (HROW, Buy, $62 PT) a company with an aggressive product acquisition strategy aiming to aggregate the eyecare space one ambulatory surgical foxhole at a time

Mayank MamtaniB.Riley Financial

B.Riley Financial

$69→$65

Buy

74.54%

Upside

Reiterated

04/01/25

Harrow price target lowered to $65 from $69 at B. RileyHarrow price target lowered to $65 from $69 at B. Riley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$37

Hold

-0.64%

Downside

Reiterated

07/12/25

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$76

Buy

104.08%

Upside

Reiterated

07/18/25

Cantor Fitzgerald Sticks to Its Buy Rating for Harrow Health (HROW)

Yi ChenH.C. Wainwright

H.C. Wainwright

$57→$60

Buy

61.12%

Upside

Reiterated

07/18/25

Harrow Health (HROW) Receives a Buy from H.C. Wainwright

Chase KnickerbockerCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

07/17/25

Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)

Lachlan Hanbury BrownWilliam Blair

William Blair

―

Buy

―

Reiterated

07/17/25

Harrow Health's Strategic Acquisition and Market Positioning Justify Buy Rating

Thomas FlatenLake Street

Lake Street

$42

Buy

12.78%

Upside

Reiterated

07/17/25

Harrow Health (HROW) Gets a Buy from Lake Street

Jeffrey CohenLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

―

Buy

―

Reiterated

07/17/25

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW)

Thomas ShraderBTIG

BTIG

$62

Buy

66.49%

Upside

Reiterated

07/01/25

First we initiated on Harrow (HROW, Buy, $62 PT) a company with an aggressive product acquisition strategy aiming to aggregate the eyecare space one ambulatory surgical foxhole at a time

Mayank MamtaniB.Riley Financial

B.Riley Financial

$69→$65

Buy

74.54%

Upside

Reiterated

04/01/25

Harrow price target lowered to $65 from $69 at B. RileyHarrow price target lowered to $65 from $69 at B. Riley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Harrow Health

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+7.91%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +7.91% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+39.24%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +39.24% per trade.

1 Year

Chase KnickerbockerCraig-Hallum

Success Rate

11/14 ratings generated profit

Average Return

+29.26%

reiterated a buy rating 9 days ago

Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +29.26% per trade.

2 Years

xxx

Success Rate

13/16 ratings generated profit

Average Return

+113.71%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +113.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HROW Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HROW has received 18 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. HROW average Analyst price target in the past 3 months is 60.00.

Each month's total comprises the sum of three months' worth of ratings.

HROW Financial Forecast

HROW Earnings Forecast

Next quarter’s earnings estimate for HROW is <$0.01 with a range of -$0.08 to $0.09. The previous quarter’s EPS was -$0.50. HROW beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year HROW has Preformed in-line its overall industry.

HROW Sales Forecast

Next quarter’s sales forecast for HROW is $66.00M with a range of $60.50M to $72.90M. The previous quarter’s sales results were $47.83M. HROW beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HROW has Preformed in-line its overall industry.

HROW Stock Forecast FAQ

What is HROW’s average 12-month price target, according to analysts?

Based on analyst ratings, Harrow Health Inc’s 12-month average price target is 60.00.

What is HROW’s upside potential, based on the analysts’ average price target?

Harrow Health Inc has 61.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HROW a Buy, Sell or Hold?

Harrow Health Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Harrow Health Inc’s price target?

The average price target for Harrow Health Inc is 60.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $76.00 ,the lowest forecast is $42.00. The average price target represents 61.12% Increase from the current price of $37.24.

What do analysts say about Harrow Health Inc?

Harrow Health Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of HROW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Harrow Health (HROW) Stock Forecast & Price Target

HROW Analyst Ratings

HROW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Harrow Health

HROW Analyst Recommendation Trends

HROW Financial Forecast

HROW Earnings Forecast

HROW Sales Forecast

HROW Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts